KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Other Non-Cash Items

Last Annual Value

-2.98M

3-Year CAGR

-35%

5-Year CAGR

-5%

10-Year CAGR

-3%

KT

Kalaris Therapeutics Inc Competitors Analysis of Other Non-Cash Items

KLRS · NASDAQ
CompanyOther Non-Cash Items
CAGR 3Y
CAGR 5Y
CAGR 10Y
-2.98M
N/AN/AN/A 
-21.90M
N/AN/AN/A
0.00
N/AN/AN/A
-971.00K
N/AN/AN/A
2.11M
243.6%-9.0%N/A
3.90M
N/AN/AN/A
19.55M
5.8%N/A118.2%
3.93M
N/A-6.2%N/A
43.21M
14.6%122.4%N/A
3.77M
N/A54.1%N/A
-85.28M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66